JAK2 and myeloproliferative neoplasm: Different studies of Riley et al. highlighted the immunomodulatory potential of IFNα by reducing the number of tumor cells through an increase of CD56bright NK-cells and a reduction of CD56dim NK-cells in the peripheral blood in patients with JAK2V617F-mutant MPN, therewith enhancing the anti-tumor immune response against JAK2-mutant MPN clones [118,125].